Key statistics
On Friday, Tempest Therapeutics Inc (3OS:DEU) closed at 1.23, 609.25% above the 52 week low of 0.173 set on Oct 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.21 |
---|---|
High | 1.29 |
Low | 1.21 |
Bid | 1.20 |
Offer | 1.23 |
Previous close | 1.26 |
Average volume | 11.30k |
---|---|
Shares outstanding | 25.21m |
Free float | 25.15m |
P/E (TTM) | -- |
Market cap | 34.03m USD |
EPS (TTM) | -1.64 USD |
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Announcements
- Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
- Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
- Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
- Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
- Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
- Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
- Tempest to Participate in Upcoming Investor Conferences
More ▼